Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History TARS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics TARS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Tarsus Pharmaceuticals Inc

TARS
Current price
43.25 USD -0.01 USD (-0.02%)
Last closed 41.40 USD
ISIN US87650L1035
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 745 693 184 USD
Yield for 12 month +59.95 %
1Y
3Y
5Y
10Y
15Y
TARS
21.11.2021 - 28.11.2021

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Address: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

74.00 USD

P/E Ratio

Dividend Yield

Financials TARS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures TARS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+182 953 000 USD

Last Year

+17 447 000 USD

Current Quarter

+78 335 000 USD

Last Quarter

+66 408 000 USD

Current Year

+170 127 000 USD

Last Year

+15 854 000 USD

Current Quarter

+73 124 000 USD

Last Quarter

+61 482 000 USD
EBITDA -107 750 000 USD
Operating Margin TTM -33.55 %
Price to Earnings
Return On Assets TTM -16.05 %
PEG Ratio
Return On Equity TTM -33.98 %
Wall Street Target Price 74.00 USD
Revenue TTM 233 674 000 USD
Book Value 8.16 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 183.70 %
Dividend Yield
Gross Profit TTM 161 562 000 USD
Earnings per share -2.70 USD
Diluted Eps TTM -2.70 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -44.91 %

Stock Valuation TARS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.03
Price Sales TTM 7.47
Enterprise Value EBITDA -3.23
Price Book MRQ 5.10

Technical Indicators TARS

For 52 Weeks

20.08 USD 57.28 USD
50 Day MA 42.20 USD
Shares Short Prior Month 8 111 634
200 Day MA 46.08 USD
Short Ratio 12.97
Shares Short 8 856 844
Short Percent 19.97 %